DIRECTORY
BIOTECH
Pharmaclient

   

Quick Click ! Monthly news Home-Site Menu-Site Contactexpress Faqs Legends Companies Events Environment Memories Home-Biotech

Abcys | AB Science | Adocia | Advicenne Pharma | Affichem | Agate Bioservices | Aisa Therapeutics | Alfact Innovation | Alizé Pharma | Ambiotis | Anaconda Pharma | Aptys Pharmaceuticals | Ariana Pharmaceuticals | Aterovax | Atlantic Bone Screen | Aureus Sciences | B Cell Design | BioAlliance Pharma | Biocortech | BioCydex | Biométhodes | Biom'up | BioProtein Technologies | BioQuanta | BioSystems International | BMSystems (Bio-Modeling) | Carmat | Cellectis | Cellial Technologies | CellProthera | CellVax | Cerenis Therapeutics | CliniGenetics | Covalab | Cytheris | Cytoo | DBV Technologies | Diaxonhit | DNA Therapeutics | Domain Therapeutics | Dynabio | Edelris | Endotis Pharma | Epixis | ERYtech Pharma | Eye Tech Care | Flamel Technologies | Fluofarma | GemacBio | Genepep | Genewave | Genfit | Genomic Vision | GenoSafe | GenoScience Pharma | Genoscreen | GenOway | Genticel | GTP Technology | Helios Biosciences | Hemarina | Hybrigenics | Hyphen BioMed | Imagene | ImmunId | Immutep | Imstar | In-Cell-Art | Indicia Biotechnology | InGen Biosciences | Innate Pharma | InnaVirVax | Innovative Health Diagnostics | IntegraGen | Ipsogen | I-Stem | Karcinolys | Keosys | MABlife | Magnisense | Mapreg | Mauna Kea Technologies | Medesis Pharma | Mellitech | Metabolys | MilleGen | Murigenetics | NanoBiotix | Neorphys | Neovacs | Netris-Pharma | Neuronax | NewVectys | NicOx | Nokad | Nosopharm | NovAliX | NovoCIB | Novotec | Obe Therapy | Oligovax | Oncodesign | OriBase Pharma | Oroxcell | Oxincell | Palumed | PharmaLeads | Pharnext | PhenoPro | Pherecydes Pharma | PolyIntell | Proteogenix | Protexel | PX'Therapeutics | Quantum Genomics | Rhenovia Pharma | ScarCell Therapeutics | Sisène Biotechnologies | Skuld-Tech | Stentys | Synapcell | Synprosis | Tc Land Expression | Theraclion | Theradiag | Theralpha | TheraVectys | Transgene | Trophos | TxCell | UROsphere | Vaxon Biotech | Vectalys | Vivalis | XenTech |

* CELLECTIS *


 

2000 - IDF
Romainville
(near Paris)
www.cellectis.com

 

Discovery, Therapy
(also Research, Subcontractor)
Key words: Genomic engineering, Meganuclease Recombination Systems (MRS), Proteins, DNA-repair
Mission: to research in, develop and market rational genome engineering technologies with 3 focus, manufacturing of proteins for therapeutic purposes, improvement of seed characteristics and development of treatments against single-gene disorders (myopathies, sickle-cell anaemia, etc.) and against the infections by DNA viruses (herpes, viral hepatitis, HIV, etc.)
Clients: Pharmaceutical industry, Biotechs, Agro industry, Research labs
Competitors: Applied Biosystems, 454 Life Sciences, Celera
mail@cellectis.com

Age: 17 year(s)

 

 

Identity
TYPE/MANAGEMENT/INVESTORSFINANCES/STATUS

Spin-off |
Managing Dir.-CEO: Choulika (André) [co-founder, born 1965, Ph.D. virology], also chairman
Oper.Dir.-COO: Simon (Mathieu) [M.D., ex-Wyeth, Pierre Fabre]
Sc.Dir.-CSO: Duchateau (Philippe) [Ph.D. science]
Tech.Dir.-CTO: Epinat (Jean-Charles) [Ph.D. science, ex-Institut Pasteur]
Fin.Dir.-CFO: Schwich (Pierre) [École des Mines (Paris), ex-Corning, Danone, Hewlett-Packard, 3i, Siparex, Next Venture)]
BusDev: Sourdive (David) [co-founder, Ph.D. virology, Polytechnique, ex-CEO]
Lic.Dir.-CBO: Pollet (Dirk) [Ph.D. biochemistry (Antwerp), ex-Dircs Consultant, Galapagos, Glaxo Welcome, Innogenetics]
Comm.Dir.: Delassus (Sylvie) [Polytechnique (1983), Ph.D., ex-Institut Pasteur, Aventis]
Financers (Hist.): Kaminvest, BankInvest, AGF P.E., Odyssée, Edmond de Rothschild, FSI, Bastid, Public
Note: website revamping, in September 2010
note : the company has created a plant division in 2011, as a major diversification

Turnover (M€) : 10.5 (2009), 9.5 (2008), 1.2 (2006)
Total funding (M€) : 110.6
Last funding (M€) : 50.0
Focus : Genome
Position : Preclin
Company confirm : none

 

History
DATEMILESTONETYPETIME
2012 .10 Partnering research agreement with National Institutes of Health (NIH, USA) and several government agencies on iPS cells, with a maximum order of services of US$ 6.9 Million over 3 years R&D [12 years]
2011 .12 Partnering research agreement with Novartis licensing-out a patent enabling to introduce new characteristics into genomes R&D [11 years]
2011 .09 Acquisition of Cellartis, the European leader in stem cell-derived in vitro R&D tools, for 16.4 M€ and 1.93 Million Cellectis shares ACQ+ [11 years]
2011 .08 Financing : fund raising subscribed by FSI and Pierre Bastid, for 50 M€ (redeemed into shares in February 2012) RFIN [11 years]
2011 .05 Licensing-out of genome customization solutions to Wako in Japan LICOUT [11 years]
2011 .04 Financing : CDC invest 6 M€ (on 12 M€ capital increase) in subsidiary Ectycell to industrially develop iPS stem cells RFIN [11 years]
2011 .03 Launch of StemRed, a program to produce red blood cells from stem cells, with public institution EFS (Etablissement Français du Sang) MKTG [11 years]
2010 .10 Set-up of US subsidiary in Cambridge, Massachussetts (Cellectis bioresearch) ORGC [10 years]
2010 .09 Acquisition of total assets of Cyto Pulse (USA) for US$ 2.2 Millions in cash ACQ+ [10 years]
2010 .03 Licensing-out of use of homologous recombination patents to Boehringer Ingelheim in order to obtain, breed and utilize animal models LICOUT [10 years]
2010 .01 Licensing-out of use of homologous recombination patents to Bayer HealthCare aimed to introduce new features into the genome LICOUT [10 years]
2009 .10 Public offering (2nd) on Euronext : 22.0 M€ (1.914 Million new shares at 11.50 € each) PBO [9 years]
2009 .10 Acquisition of Vectocell Technology from Diatos assets (bankrupt in May 2009), to accelerate therapeutic development programs ACQ+ [9 years]
2009 .09 Set-up of Ectycell, a subsidiary specialized in stem cells from adults ORGC [9 years]
2009 .06 Launch of cGPS Custom, new kits for targeted gene integration in native cell lines, by affiliate Cellectis BioResearch (later extended to human cell lines and in gene function studies) MKTG [9 years]
2008 .12 Launch of PI10.3, a new research kit for producing stable cell clones using gene targeting in just 4 weeks, by affiliate Cellectis BioResearch MKTG [8 years]
2008 .11 Research : publication in Nature Magazine on a Therapeutic Meganuclease to treat a severe skin inborn disease by the CNIO, the CRG and Cellectis R&D [8 years]
2008 .09 Financing agreement by AFM (French Muscular Dystrophy Association), 8.3 M€ granted over 5 years for research on 7 genes surgery of orphan diseases RFIN [8 years]
2008 .06 Court : legal dispute on patents against Shionogi LEGAL [8 years]
2008 .05 Set-up of 2 new subsidiaries in France, Cellectis Bioresearch and Cellectis Genome Surgery ORGC [8 years]
2007 .02 Listing on Euronext Paris : 21.2 M€ PBO [7 years]
2005 .06 3rd round-financing : 5.6 M€, by BankInvest, AGF P.E., Odyssée, Edmond de Rothschild (follow-up) RFINC [5 years]
2004 .04 Company move from Paris (Institut Pasteur) to Biocitech in Romainville ORGL [4 years]
2002 .05 2nd round-financing : 8.0 M€, by BankInvest, AGF PE, Odyssée, Edmond de Rothschild RFINB [2 years]
2000 .11 1st round-financing : 3.8 M€, by Kaminvest RFINA [0 year]
2000 .06 Licensing-in of 6 lead products from Institut Pasteur (spin-off with equity) LICIN [0 year]
2000 .01 Company founded by André Choulika and David Sourdive ORGF [0 year]

Actualisation / Updating: 4-Mar-2013

   


Pharmaclient est le site-conseil de la Valorisation Client en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, Insertion dans la base Biotech, ou Question: CONTACT



© J.H. Huber, Pharmaclient 2001-2017. Pour retourner à la page d'accueil Biotech: BIENVENUE !       Haut de page : légende